What is Allogene Therapeutics Forward Dividend Yield %?
As of today (2024-05-14), the Forward Annual Dividend Yield of Allogene Therapeutics is 0.00%.
As of today (2024-05-14), the Trailing Annual Dividend Yield of Allogene Therapeutics is 0.00%.
ALLO's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.5 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Allogene Therapeutics's Forward Dividend Yield %
For the Biotechnology subindustry, Allogene Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allogene Therapeutics's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Allogene Therapeutics's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Allogene Therapeutics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Allogene Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Allogene Therapeutics (Allogene Therapeutics) Business Description
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALLO has been successfully added to your